Omega-3 fatty acids ameliorate proteinuria but not renal function in iga nephropathy: A meta-analysis of randomized controlled trials

Nephron - Clinical Practice

Volumn 121, Issue 1-2, 2012, Pages

  Chou, Hsin Hsu ^a   Chiou, Yuan Yow ^a,c   Hung, Peir Haur ^a   Chiang, Pei Chung ^a   Wang, Shan Tair ^b  

^a School of Medicine   (Taiwan)

^b CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Fish oil; IgA nephropathy; Meta analysis; Omega 3 fatty acids

Indexed keywords

OMEGA 3 FATTY ACID; PLACEBO;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; LOW DRUG DOSE; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CREATININE; FATTY ACIDS, OMEGA-3; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871667302     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000341929     Document Type: Article

References (22)

1. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. QJ Med 1987; 64: 709-727.
2. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, Andre C, Adnot S: Immunomodulation with low-dose immunoglobulins for moderate IgAN and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 1995; 69: 327-334.
3. Schena FP: Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for the physicians and nephrologists. Am J Med 2001; 110: 499-500.
4. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA: Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003; 4:CD003965.
5. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-2097. (Pubitemid 41716440)
6. Floege J, Eitner F: Present and future therapy options in IgA nephropathy. J Nephrol 2005; 18: 354-361. (Pubitemid 41700096)
7. Dillon, JJ: Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739-1744.
8. Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Oxford, Wiley, 2008, pp 277-278.
9. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D: Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a 'very low dose' regimen. Ren Fail 2004; 26: 453-459. (Pubitemid 39167623)
10. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with icosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol 1989; 31: 128-131. (Pubitemid 19080448)
11. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE: A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-1199. (Pubitemid 24331337)
12. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S: Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009; 24: 156-160.
13. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, Bjorkhem I, Bergstrom J: Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994; 41: 183-190. (Pubitemid 24104881)
14. De Caterina R, Endres S, Kristensen SD, Schmidt DB: n-3 fatty acids and renal diseases. Am J Kidney Dis 1994; 24: 397-415. (Pubitemid 24277936)
15. Stone NJ: Fish consumption, fish oil, lipids, and coronary artery disease. Circulation 1996; 94: 2337-2340. (Pubitemid 26360549)
16. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-2757. (Pubitemid 35364932)
17. Nordoy A, Marchioli R, Arnesen H: n-3 polyunsaturated fatty acids and cardiovascular disease. Lipids 2001; 36:S127-S129. (Pubitemid 34106222)
18. Hamazaki T, Tateno S, Shishido H: Eicosapentaenoic acid and IgA nephropathy. Lancet 1984;i:1017-1018. (Pubitemid 14148918)
19. Cheng IK, Chan PC, Chan MK: The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 1990; 5: 241-246. (Pubitemid 20204465)
20. Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GFM: Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; 16: CD003962.
21. Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC, North American IgA Nephropathy Study Group: Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage-and size-dependent. Clin J Am Soc Nephrol 2006; 1: 1167-1172.
22. Donadio JV, Bergstralh EJ, Bibus DM, Grande JP: Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy? Clin J Am Soc Nephrol 2006; 1: 933-939.